行情

BLRX

BLRX

BioLine RX
NASDAQ

实时行情|Nasdaq Last Sale

2.410
-0.070
-2.84%
已收盘, 16:00 01/29 EST
开盘
2.480
昨收
2.480
最高
2.530
最低
2.390
成交量
2.02万
成交额
--
52周最高
13.05
52周最低
1.550
市值
2,362.12万
市盈率(TTM)
-1.0023
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLRX 新闻

  • BioLineRx Concludes Recruitment in Pancreatic Cancer Study
  • Zacks.6天前
  • BioLineRx completes enrollment in mid-stage BL-8040 study
  • seekingalpha.01/22 18:13
  • BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
  • PR Newswire.01/22 12:00
  • BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
  • Zacks.01/15 14:56

更多

所属板块

生物技术和医学研究
-0.29%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

BLRX 简况

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.
展开

Webull提供BioLineRX Ltd.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。